FTY720-P, a Biased S1PR Ligand, Increases Mitochondrial Function through STAT3 Activation in Cardiac Cells

Area of Science:

• Cardiovascular Biology
• Metabolic Research
• Pharmacology

Background:

• FTY720, an FDA-approved drug for multiple sclerosis, modulates sphingosine 1-phosphate receptors.
• Drug repurposing suggests FTY720 benefits metabolic health and cardiac function, but mechanisms are unclear.

Purpose of the Study:

• To investigate the molecular mechanisms by which FTY720 impacts cellular metabolism, specifically focusing on mitochondrial function.
• To determine if FTY720 affects mitochondrial respiration and ATP production in human cardiomyocytes.

Main Methods:

• Utilized AC16 human cardiomyocyte cells treated with nanomolar concentrations of phosphorylated FTY720 (FTY720-P).
• Assessed mitochondrial respiration, ATP production rates, mitochondrial nucleoid counts, and morphology.
• Investigated the role of STAT3 activation using a STAT3 inhibitor.

Main Results:

• FTY720-P significantly activated mitochondrial respiration and ATP production in cardiomyocytes.
• Observed increases in mitochondrial nucleoid numbers and alterations in mitochondrial morphology.
• FTY720-P induced STAT3 activation, which was crucial for its effects on mitochondrial function, as shown by inhibitor studies.

Conclusions:

• FTY720 enhances mitochondrial function and ATP production in human cardiomyocytes.
• The mechanism involves, in part, the activation of the transcription factor STAT3.
• These findings provide new insights into FTY720's metabolic benefits and potential cardioprotective effects.